Shift toward early-stage deals favors bioteochs

Article Abstract:

Biotech firms are shifting towards preclincal and early-stage deals to attract pharmaceutical firms, which are favoring such deals in their bid to acquire a potential blockbuster drug at the earliest instance. Phase 1 and preclinical deals doubled their share to about 15% in 2005 from 7% in 2001 as the total value of research partnership between pharmaceutical and biotech firms reached almost $11 billion.

United States, Pharmaceutical preparations, Alliances, partnerships, Pharmaceutical industry, Alliances and partnerships

---

Public biotech 2006- the numbers

Article Abstract:

The analysis of 419 publicly traded on stock exchanges biotech firms in 2006 reported a great boost in the biotech revenue and expeniture on research but became less profitable.

Sales & consumption, Evaluation, Research grants, Research funding, Industry sales and revenue

---

Similar abstracts:

• Abstracts: Profiles of food & beverage firms. Edelman faces off vs. NHL owners. Profiles of financial PR firms
• Abstracts: Conflicting messages. 2006: Hopes and dangers. Threatening US deficit
• Abstracts: Super Citrimax Wired Energy Drinks. Kizz-Me Energy Drinks
• Abstracts: Granite Gold Penetrating Sealer; Polish/Protector Sprays. Earth Friendly Products Uni Fresh Air Freshner Sprays
• Abstracts: IABC hurt by poor communications. Public sees PR as a sales tool

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.